雷帕鸣价格贵不贵

November 29, 1978, the anniversary of Biocon, was the beginning of India's Biorevolution. Biocon India was registered as a joint venture between Biocon Biochemical Co., Ltd., and the chairman of the company is an entrepreneur from Ireland and India: Ms. Kiran Sujishaw. It is a drug produced by the Indian company Biocon for the treatment of patients undergoing kidney transplantation and the prevention of organ rejection.

Leipaming was launched in China at the end of 2003. In terms of price, Medical Travel has learned that the price of Rapamin produced by Biocon in India is around $200.

Rapamin is a triangular white or off-white sugar-coated tablet. Rapamin is suitable for patients receiving kidney transplants to prevent organ rejection. It is recommended to be used in combination with cyclosporine and corticosteroids. Rapamin is recommended for combined use with cyclosporine and corticosteroids. Take orally, once daily. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose of rapamycin should be three times the maintenance dose.

Rapamin is suitable for patients receiving kidney transplants to prevent organ rejection. Clinical recommendations include the combined use of rapamycin with cyclosporine and corticosteroids. This medicine should be started as soon as possible after transplantation. For new transplant recipients, the loading dose of this drug should be taken for the first time, that is, 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. Although the loading dose of 15 mg and the maintenance dose of 5 mg/day used in clinical trials are safe and effective, the therapeutic benefits of doses above 2 mg are unclear for kidney transplant patients.

First of all, after kidney transplant surgery, it is generally required to have weekly follow-up visits within two to three months. First, the concentration of anti-rejection drugs must be observed, because the bioavailability of anti-rejection drugs has very large individual differences. It must be maintained at an ideal level, and it is not good for the patient if the concentration is high or low. If the concentration is too high, poisoning may occur and creatinine will increase. Rejection may occur if the concentration is too low. Therefore, post-operative care requires regular follow-up visits.

The adverse reaction was hyperlipidemia (56.5%, 13 cases/23 cases). After reducing the dosage or applying lipid-lowering drugs, the patient's blood lipids dropped to normal or slightly higher than normal levels. Graft vascular disease and cardiovascular complications have not increased since follow-up.

Recommended related hot articles: /newsDetail/87033.html